Sequent is down 60% from its highs. Let's understand how their business is faring (by @AnishA_Moonka )

A thread 🧵👇

1/ How do businesses happen? Do they just crop up the day when an entrepreneur thinks of it? Do they become bigger as the stock reaches new highs?

I guess, No. It takes time, It takes labor. Again, Will the ascension be smooth? Never.

The journey of Sequent in the last 5 yrs:
2/ Pre-FY15: Sequent was merely a commodity high volume low-value API player

Due to this intrapreneur's (Mr. Manish Gupta) efforts that we see Sequent as the only USFDA approved generic animal player from 🇮🇳

Behind the deals of Strides Agila plant & the Australian business.
3/ The transformation speaks volumes of how such a businessman thinks.

In 6yrs of existence, he has taken the unknown co. to be among the Top 20 in the world.

Now, he is taking a long shot to enter the Top 10 over the next decade (aka. Sequent 2.0); A tall task.
4/ If he is dreaming big & has executed in the past with industry tailwinds; the common question is why is the stock down by so much?

Probabilities: Investors went from a high probability of success to a low in months as multiple obstacles (short term?) hit the co.
5/ Again, It's not all hunky Dory.

While the rev growth is better than the industry, the co. has been struggling with margins for the last 2-3 quarters.

There are multiple obstacles & we will discuss them one by one.
6/ This quarter the gross margins have dropped to a 5yr low of 42.8%.

Particularly, the China power issue again (as I had discussed in my Laurus thread)

A sharp rise in input costs & given a B2B company; passing on takes a long time & is usually a difficult conversation.
7/ While it is visible that China+1 is playing out in the broad sense; the dependence on our neighbors is not going anytime soon, at least not for 2-3yrs

Such disruptions are a risk. Also, Higher inventories are an outcome (Higher Working capital)

Anyway, it will get passed on.
8/ Another risk that played out was of much lower orders in the API business especially Albendazole.

While the portfolio continues to grow in number & rev (up 25% in Q2FY22); the albendazole API degree by a lot leading to 10% regrowth overall

Stockpiling last year, hurt them.
9/ The biggest risk remains the Turkish Lira devaluation: Not even a forex expert knows

Sequent does get the benefit of a weaker currency to export (use Turkey as its supply base); however, the Turkey domestic biz gets hurt: In Q2 they grew 11% in cc but degree 7% in real terms.
10/ However, let's talk positives now

- Big Opportunity: $51B industry globally growing at 5-6% cagr
- Strong R&D efforts (Formulations & APIs) to drive the next leg of growth
- Major capacity expansion over FY22-23: focused on regulated markets
11/ - Top industry veterans induced into the board in the last year with a focus toward maximizing the Terminal value
- Optionality: CDMO & CMO contracts with Top 10 global Animal Healthcare cos.
- Capacity to suffer: Investing 200crs over the next 2 yrs in capability building.
12/ To summarise, there are multiple strands one can write on this niche industry with very strong economics once scale is reached. Think Zoetis.

However, I aspired to just clarify the misinterpretations. Let me know in the comments about your thoughts on Sequent 2.0 😸

End.
If you found the thread to be of help, please retweet the 1st tweet 👇 to help us educate more investors.
https://t.co/MP3T5Gepm6

More from JST Investments

You May Also Like

Moderna CEO Stephane Bancel was previously CEO of bioMerieux in France from 07-10.

Alain Merieux, who owns bioMerieux, was instrumental in the creation of the Wuhan Institute of Virology P4 Lab.

The same people who helped create the virus, also helped to create the vaccines...


Moderna partnered with French Pasteur Institute in 2015 to develop mRNA vaccine technology.

Pasteur Institute partnered with the Wuhan P4 Laboratory in 2017 along with the Merieux Foundation to study emerging viruses...
https://t.co/yFsHwrNYaK
https://t.co/9M5lydBKhM


Nobel prize winning scientist Luc Montagnier asserts that Sars-Cov-2 is man-made and originated from the Wuhan Institute of Virology.

Montagnier did extensive work with the Pasteur Institute in France which was partnered with the Wuhan P4.

Merieux Foundation & the Chinese government have worked together since 1965, and partnered to study emerging pathogens in Africa in 2015.

Their research included "PATHOGENS CARRIED BY BATS" that provoke respiratory diseases.

🚨🚨🚨
https://t.co/gVwpT0ssqI
The first ever world map was sketched thousands of years ago by Indian saint
“Ramanujacharya” who simply translated the following verse from Mahabharat and gave the world its real face

In Mahabharat,it is described how 'Maharishi Ved Vyasa' gave away his divine vision to Sanjay


Dhritarashtra's charioteer so that he could describe him the events of the upcoming war.

But, even before questions of war could begin, Dhritarashtra asked him to describe how the world looks like from space.

This is how he described the face of the world:

सुदर्शनं प्रवक्ष्यामि द्वीपं तु कुरुनन्दन। परिमण्डलो महाराज द्वीपोऽसौ चक्रसंस्थितः॥
यथा हि पुरुषः पश्येदादर्शे मुखमात्मनः। एवं सुदर्शनद्वीपो दृश्यते चन्द्रमण्डले॥ द्विरंशे पिप्पलस्तत्र द्विरंशे च शशो महान्।

—वेद व्यास, भीष्म पर्व, महाभारत


Meaning:-

हे कुरुनन्दन ! सुदर्शन नामक यह द्वीप चक्र की भाँति गोलाकार स्थित है, जैसे पुरुष दर्पण में अपना मुख देखता है, उसी प्रकार यह द्वीप चन्द्रमण्डल में दिखायी देता है। इसके दो अंशो मे पीपल और दो अंशो मे विशाल शश (खरगोश) दिखायी देता है।


Meaning: "Just like a man sees his face in the mirror, so does the Earth appears in the Universe. In the first part you see leaves of the Peepal Tree, and in the next part you see a Rabbit."

Based on this shloka, Saint Ramanujacharya sketched out the map, but the world laughed